EGFR and colorectal carcinoma: In addition to conventional chemotherapy drugs, several agents targeting the molecular drivers of CRC pathogenesis, including signaling pathways mediated by the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor, have been applied in such patients, with increasing survival rates [4–8].